• AAPL 189.82
  • TSLA 177.46
  • AMZN 184.7
  • MSFT 420.21
  • INTC 31.85
  • EURUSD 1.0872
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. KO /
  3. 005680.KO

Samyoung Elec (005680 KO) stock market data APIs

₩10440 -20(-0.2%) as of May 17, 2024

Samyoung Elec Financial Data Overview

10460
10440
-
10600
10290
7800-12110
209 200 M
20 000 K
177 290 M
174.442
0.539
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: '005680',
Type: 'Common Stock',
Name: 'Samyoung Elec',
Exchange: 'KO',
CurrencyCode: 'KRW',
CurrencyName: 'Korean Won',
CurrencySymbol: '₩',
CountryName: 'Korea',
CountryISO: 'KR',
OpenFigi: NULL,
ISIN: 'KR7005680004',
CIK: NULL,
EmployerIdNumber: '',
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: 'International',
Sector: 'Technology',
Industry: 'Electronic Components',
}

Samyoung Elec Fundamental Data is available in our Financial Data APIs

  • Net Revenue 177 290 M
  • EBITDA 13 670 M
  • Earnings Per Share
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Samyoung Elec Earnings via APIs

  • Latest Release 2024-05-14
  • EPS/Forecast NaN

Get Samyoung Elec End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Samyoung Elec latest news via APIs

Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients eligible for targeted treatment with LORBRENA (lorlatinib)

-- About 235,000 people in the US will be diagnosed with lung cancer in 2021, with non-small cell lung cancer (NSCLC) accounting for 84 percent of all lung cancers(1) -- ALK - anaplastic lymphoma kin...
  • ASSAY
  • CANCER
  • CANCER BIOMARKER
  • COMPANION DIAGNOSTIC
  • FDA
  • LUNG CANCER
  • LUNG CANCERS
  • PROGRESSION-FREE SURVIVAL
  • ROCHE GROUP
  • TARGETED THERAPIES
  • VENTANA

Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients eligible for targeted treatment with LORBRENA (lorlatinib)

-- About 235,000 people in the US will be diagnosed with lung cancer in 2021, with non-small cell lung cancer (NSCLC) accounting for 84 percent of all lung cancers(1) -- ALK - anaplastic lymphoma kin...
  • ASSAY
  • CANCER
  • CANCER BIOMARKER
  • COMPANION DIAGNOSTIC
  • FDA
  • LUNG CANCER
  • LUNG CANCERS
  • PROGRESSION-FREE SURVIVAL
  • ROCHE GROUP
  • TARGETED THERAPIES
  • VENTANA
Do you have any questions?
support@eodhistoricaldata.com